On May 31, 2019 Iovance Biotherapeutics, a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, reported that it has expanded its relationship with WuXi AppTec’s Advanced Therapies Business Unit (WuXi ATU) (Press release, Iovance Biotherapeutics, MAY 31, 2019, View Source [SID1234536741]). WuXi will increase capacity for Iovance’s innovaTIL-01 and innovaTIL-04 studies, which offer lifileucel and LN-145 for treatment of metastatic melanoma and recurrent, metastatic, or persistent cervical cancer, respectively.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to continue our partnership with WuXi," said Maria Fardis, Ph.D., MBA, President and Chief Executive Officer of Iovance. "Being able to expand our relationship in order to broaden patient access to our treatments is very important to us. WuXi has been a strong partner in developing the Iovance TIL product and we look forward to further expansion of our ongoing relationship."

Felix Hsu, SVP and Global Head of WuXi Advanced Therapies, said, "We are pleased to expand our relationship and manufacturing partnership with Iovance, and look forward to helping to accelerate and expand their clinical trials where possible, so more patients get access to their treatments and the benefits they provide." WuXi manufactures TIL products for Iovance at its Commerce Center 3 facility, a 55,000-square-foot late phase and commercial manufacturing facility for cell therapies. It is one of three facilities in the Philadelphia Navy Yard supporting the development, manufacturing and quality control testing of cell and gene therapies.